Table 1.
Clinicopathologic information of the endometrial clear cell carcinomas included in this study.
| Case ID |
Age at diagnosis (years) |
FIGO stage at presentation |
Architectural pattern (%) | Nuclear grade |
Mitotic index** |
p53 IHC |
ARID1A IHC |
DNA MMR IHC | Follow-up (months, status) |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Papillary | Tubulocystic | Solid | |||||||||
| CC01 | 73 | IB | 50 | 50 | 2 (focal 3) | 18 | Null | Retained | Retained | 31, NED*** | |
| CC02 | 74 | IV | 40 | 30 | 30 | 2 (focal 3) | 8 | Positive | Retained | Retained | 23, DOD |
| CC03* | 62 | IV | 40 | 40 | 20 | 2 (focal 3) | 5 | Wild-type | Retained | Retained | 30, DOD |
| CC04 | 51 | IA | 80 | 20 | 2 | 4 | Wild-type | Loss | Retained | 16, DOD | |
| CC05 | 59 | IA | 90 | 10 | 2 | 5 | Wild-type | Loss | MLH1/PMS2 loss | 65, NED | |
| CC06 | 83 | IA | 50 | 50 | 2 | 8 | Wild-type | Loss | Retained | 60, DOD | |
| CC07 | 62 | IV | 40 | 60 | 2 (focal 3) | 16 | Positive | Retained | Retained | 5, DOD | |
| CC08 | 68 | IA | 70 | 30 | 2 | 5 | Wild-type | Retained | Retained | 69, NED | |
| CC10* | 54 | IA | 100 | 2 (focal 3) | 1 | Wild-type | Retained | MSH6 loss | 50, NED | ||
| CC11 | 65 | IA | 100 | 2 | 1 | Wild-type | Loss | MSH6 loss | 83, NED | ||
| CC12 | 61 | IV | 30 | 70 | 2 (focal 3) | 4 | Wild-type | Retained | Retained | 26, DOD | |
| CC13 | 65 | IV | 80 | 20 | 2 (focal 3) | 17 | Positive | Retained | Retained | 8, DOD | |
| CC14 | 70 | IV | 40 | 60 | 2 | 3 | Wild-type | Retained | Retained | 6, DOD | |
| CC15 | 78 | IV | 50 | 50 | 2 | 3 | Positive | Retained | Retained | 53, DOD | |
| CC16 | 63 | IV | 50 | 50 | 2 (focal 3) | 8 | Null | Retained | Retained | 6, DOD | |
| CC17 | 56 | IIIC | 60 | 40 | 2 | 6 | Positive | Retained | Retained | 55, AWD | |
| CC18 | 72 | IA | 50 | 50 | 2 (focal 3) | 2 | Wild-type | Partial loss | Retained | 93, NED | |
| CC19 | 71 | IA | 50 | 50 | 2 | 2 | Wild-type | Retained | Retained | 6, DOC | |
| CC20 | 63 | IIIC | 50 | 50 | 2 | 12 | Wild-type | Loss | MLH1/PMS2/MSH6 loss | 36, NED | |
| CC21 | 66 | IA | 50 | 50 | 2 | 8 | Wild-type | Retained | Retained | 105, AWD | |
| CC22 | 62 | IA | 30 | 70 | 2 (focal 3) | 8 | Wild-type | Retained | Retained | 13, DOD | |
| CC23 | 58 | IV | 30 | 70 | 2 (focal 3) | 2 | Positive | Retained | Retained | 39, AWD | |
| CC24 | 71 | IA | 40 | 40 | 20 | 2 (focal 3) | 4 | Positive | Retained | Retained | 14, NED |
| CC25 | 65 | IA | 70 | 30 | 2 (focal 3) | 9 | Wild-type | Retained | Retained | 21, NED | |
| CC26 | 65 | IA | 20 | 20 | 60 | 2 | 2 | Wild-type | Retained | MSH6 equivocal | 20, NED |
| CC27 | 64 | IA | 50 | 50 | 2 (focal 3) | 8 | Wild-type | Retained | Retained | 61, NED | |
| CC28 | 64 | IV | 100 | 2 (focal 3) | 5 | Positive | Retained | Retained | 8, DOD | ||
| CC29 | 67 | IV | 25 | 25 | 50 | 2 | 2 | Wild-type | Loss | Retained | 65, DOD |
| CC31 | 55 | IA | 10 | 90 | 2 | 9 | Wild-type | Retained | MSH6 loss | 66, NED | |
| CC33 | 33 | IV | 20 | 80 | 2 | 2 | Null | Retained | Retained | 10, DOD | |
| CC34 | 70 | IV | 40 | 30 | 30 | 2 (focal 3) | 3 | Wild-type | Retained | Retained | 27, NED |
| CC35 | 81 | IV | 40 | 30 | 30 | 2 | 8 | Wild-type | Retained | Retained | 14, DOD |
*
Sequencing data not available;
**
Mitotic index defined as number of mitoses per 10 high-power fields;
***
Lost to follow-up
AWD, alive with disease; DOC, died of other cause; DOD, died of disease; IHC, Immunohistochemistry; MMR, mismatch repair; NED, no evidence of disease; Null, null phenotype.